Search results
-
ASH 2024 preview – more challenges to the BTK order
… Nurix and BeiGene's BTK degraders, which went toe to toe at ASH 2023 and then put up impressive data at this year's …
- 11/14/2024 - 15:27 -
ASH 2024 preview – multiple myeloma in focus
… project BMS-986393. This reported first phase 1 results at ASH 2023, showing an 88% response rate among 73 patients, …
- 11/13/2024 - 12:23 -
New Roche/Poseida project isn’t P-BCMACD19-ALLO1
… of which yielded confounding multiple myeloma data at ASH 2023 ; the dataset now stands at 72 patients, with an …
- 10/22/2024 - 13:43 -
Xencor “still committed” to oncology
… acute leukaemia & T-cell lymphoblastic leukaemia Data at ASH 2023, 2/12 CRs; no longer listed in pipeline …
- 09/10/2024 - 08:01 -
Front-line setting next for axatilimab
… Ph2 Agave-201, monotherapy Approved in US, data at ASH 2023 First line Ph2 Jakafi combo …
- 08/15/2024 - 13:37 -
EHA 2024 preview – Novartis doubles up
… Anti-BCMA Car-T S207 Ph1 results, last updated at ASH 2023 Bristol Myers Squibb Golcadomide … Nurix NX-5948 BTK degrader S155 Had data at ASH 2023 BeiGene BGB-16673 BTK degrader S157 Had data at ASH 2023 Kymera KT-333 Stat3 degrader …
- 05/20/2024 - 18:11 -
Innate gets a new lacutamab blow
… KIR3DL2 expressing) Ph2 Tellomak Final data at ASH 2023: 38% ORR in 56 pts Innate to submit Sézary and …
- 03/21/2024 - 15:43 -
Takeda ploughs a lonely CD38 furrow
… Biosciences China ph2 * uncontrolled trial, data at ASH 2023; China ph2 * placebo-controlled trial completes …
- 06/24/2024 - 11:58 -
After Dreamm-7, how about more multiple myeloma conjugates?
… Pharma/ Huadong Medicine $20m Asia deal; ph1 data at ASH 2023, 0% ORR in 12 patients Ispectamab …
- 02/13/2024 - 14:31 -
Gilead deals more checkpoint disappointment
… HLA-G-targeting CIR-NK cells Preclinical data at SITC & ASH 2023 AR087 Y Biologics Anti-HLA-G MAb …
- 02/12/2024 - 10:40
